ライフサイエンスコーパス: proton pump

1 r-type ATPase (V-ATPase), a heteromultimeric proton pump.

2 ein on earth and functions as a light-driven proton pump.

3 r protons, limiting luminal acidification by proton pumps.

4 models describing the molecular mechanism of proton pumping.

5 ain their optical properties associated with proton pumping.

6 and 22nm, respectively, that did not disrupt proton pumping.

7 two-state stabilization-change mechanism of proton pumping.

8 driven rotation by blocking ATPase-dependent proton pumping.

9 Proton pumping A-type cytochrome c oxidase (CcO) termina

10 ed in the process to thermodynamically drive proton pumping across its membrane domain.

11 role in many biochemical processes, such as proton pumping across membranes and enzyme catalysis.

12 d couples the free energy of the reaction to proton pumping across the membrane.

13 Low cytosolic pH required increased proton pumping across the thylakoid membrane and elevate

14 Thus, the interplay between auxin, proton pump activation and expansin action may be more f

15 ver, forced acidification through artificial proton pump activation inhibits root cell elongation.

16 ver, forced acidification through artificial proton pump activation inhibits root cell elongation.

17 Thus, the interplay between auxin, proton pump activation, and expansin action may be more

18 DH:O(2) activities and supported NADH-linked proton pumping activities in the host membranes almost a

19 let simultaneously measured the light-driven proton-pumping activities of each bio-pixel.

20 membrane H(+)-ATPase complex, thus reducing proton pump activity to close stomata.

21 on of endosomes resulting from inhibition of proton pumping activity of vacuolar-type H(+)-ATPase (v-

22 embrane protein that synthesizes ATP through proton-pumping activity across the membrane.

23 akage permeability but significantly reduced proton-pumping activity compared with M2 phagosomes.

24 The proton-pumping activity contributes to the proton electr

25 While proton-pumping activity was disrupted in many of the spe

26 ATP-hydrolase activity, which is coupled to proton-pumping activity.

27 of the C-terminal domain enabled ATPase and proton-pumping activity.

28 cate a common mechanism of regulation of the proton pump and a potassium channel, two essential eleme

29 ith impaired activity of the plasma membrane proton pump and the V-ATPase complex.

30 aling during cell expansion that coordinates proton pumping and cellulose synthesis.

31 unt the transmembrane potential generated by proton pumping and is capable of restoring microbicidal

32 of E286 is increased, which slows down both proton pumping and the chemical catalysis.

33 86 through the D-channel, which impairs both proton pumping and the chemical reaction.

34 ause of its spatial separation from both the proton pumps and the ATP synthase.

35 requires extensive adaptations of membranes, proton pumps, and DNA repair mechanisms.

36 tegy to selectively express the light-driven proton pump Arch3 on synaptic vesicles.

37 The light-activated inhibitory proton pump Archaerhodopsin (Arch) was expressed under c

38 The proton pump Archaerhodopsin-3 (Arch), an optogenetic too

39 sly available optogenetic tools, such as the proton pump archaerhodopsin-3 (Arch).

40 ction of two different component opsins: the proton pump, Archaerhodopsin and a chloride channel opsi

41 t, following activation of a light-activated proton pump, Archaerhodopsin-3 (Arch), proton transients

42 cent protein H2B-GFP and the light-activated proton pump ArchT.

43 Retinal bound light-driven proton pumps are widespread in eukaryotic and prokaryoti

44 acceptor and donor, a hallmark of rhodopsin proton pumps, are conserved in these cryptophyte protein

45 provides a steadily amplifying advantage to proton pumping as membrane permeability falls, for the f

46 ma mutants) have reduced levels of the Pma1p proton pump at the plasma membrane and increased levels

47 ubic phase SFX structure of the light-driven proton pump bacteriorhodopsin (bR) to 2.3 A resolution a

48 o haloarchaeal rhodopsins, in particular the proton pump bacteriorhodopsin (BR), than to earlier know

49 ion pump halorhodopsin (HR) and the outward proton pump bacteriorhodopsin (BR).

50 elease and uptake events in the light-driven proton-pump bacteriorhodopsin and correlate these to oth

51 Shifting the action spectra of these proton pumps beyond 700 nm would generate new prospects

52 ichia coli F1Fo ATP-synthase and the primary proton pump bo3-oxidase, into synthetic lipid vesicles w

53 S1 and the V1A subunit of the H(+) V-ATPase (proton pump) by co-immunoprecipitation in human embryoni

54 Virtual proton pumping can only be achieved by Arg(+)/Agm(2+) ex

55 Proton-pumping complex I of the mitochondrial respirator

56 r H(+)-ATPase (V-ATPase) is an ATP-dependent proton pump composed of a peripheral ATPase domain (V1)

57 ar (H(+))-ATPases (V-ATPases) are ATP-driven proton pumps composed of a peripheral V1 domain and a me

58 w-micromolar levels of sulfide inhibited the proton-pumping cytochrome bo oxidase that is regarded as

59 gh the D-channel is kinetically favored over proton pumping due to the loss of a kinetic gate in the

60 internal proton transport events that enable proton pumping during first steps of oxidation of the fu

61 he D-channel is imperative to achieving high proton-pumping efficiency in the WT CcO.

62 d Ca(2+) channels and activates H(+) -ATPase proton pump efflux that dissociates periplasmic AGP-Ca(2

63 pHoenix, can functionally replace endogenous proton pumps, enabling optogenetic control of vesicular

64 Coxs studied to date are redox-driven proton-pumping enzymes belonging to one of three subfami

65 olar H(+)-ATPase (V-ATPase) is an ATP-driven proton pump essential to the function of eukaryotic cell

66 This essential proton pump exists in two activity states: an autoinhibi

67 ome c oxidoreductase, which transitions to a proton-pumping Fd(red): nicotinamide adenine dinucleotid

68 tained in coculture, Rnf likely functions as proton-pumping ferredoxin (Fd): type-I cytochrome c oxid

69 f the Vacuolar H+ ATPase (V-ATPase), the key proton pump for endo-lysosomal acidification, and two pr

70 oichiometry of complex I (i.e. the number of protons pumped for each two electrons transferred) under

71 opsin (BR) is a heptahelical light-dependent proton pump found in the purple membrane of the archaeon

72 channel that impair, and sometimes decouple, proton pumping from the chemical catalysis.

73 Besides its canonical proton-pumping function, V-ATPase's membrane sector, Vo,

74 These conditions affect the light-driven proton pumping functional exertion as well.

75 The gastric proton pump H(+),K(+)-ATPase acidifies the gastric lumen

76 ND5 is a proton pump, helping to maintain the coupling gradient i

77 arly all aerobic organisms are terminated by proton-pumping heme-copper oxygen reductases (HCOs).

78 Complex I functions as a redox-driven proton pump in aerobic respiratory chains.

79 lar simulations to study the function of the proton pump in complex I from Thermus thermophilus The s

80 Complex I functions as a redox-linked proton pump in the respiratory chains of mitochondria an

81 h earlier biochemical data, suggest that the proton pumping in complex I is activated by a unique com

82 tion step that could thermodynamically drive proton pumping in complex I.

83 tructure and decreased V-ATPase activity and proton pumping in isolated vacuolar vesicles.

84 We make use of the physical mechanism of proton pumping in the so-called Complex I within mitocho

85 Likewise, up-regulation of the potassium and proton pumps in the laboratory strain enhances performan

86 (OR 2.43(2.06-2.88) and 1.90 (1.68-2.14) for proton pump inhibitor (PPI) and histamine 2 receptor ant

87 t in vitro and animal studies have found the proton pump inhibitor (PPI) lansoprazole to be highly ac

88 esponse (SVR) included age, race, cirrhosis, proton pump inhibitor (PPI) prescription, prior HCV trea

89 Esophageal eosinophilia can be proton pump inhibitor (PPI) resistant or responsive, rep

90 ficance and plausible mechanisms underlying 'proton pump inhibitor (PPI) responsive oesophageal eosin

91 ageal reflux disease (GERD) symptoms despite proton pump inhibitor (PPI) therapy (partial responders)

92 RD) commonly starts with an empiric trial of proton pump inhibitor (PPI) therapy and complementary li

93 Inadequate response to proton pump inhibitor (PPI) therapy in patients with gas

94 This study assessed the effect of proton pump inhibitor (PPI) therapy on the volume, distr

95 Partial response to proton pump inhibitor (PPI) therapy poses a healthcare c

96 Demographics, duration of symptoms and proton pump inhibitor (PPI) therapy, GERD-Health Related

97 some patients whose symptoms persist despite proton pump inhibitor (PPI) therapy.

98 referral of TS, in patients without previous proton pump inhibitor (PPI) treatment and in patients on

99 : Studies have reported associations between proton pump inhibitor (PPI) use and dementia.

100 were hospitalized and they had higher MELD, proton pump inhibitor (PPI) use and HE without differenc

101 0.13), perioperative outcome, regurgitation, proton pump inhibitor (PPI) use, lower esophageal sphinc

102 On the second day of investigation, proton pump inhibitor (PPI) was given at a mean dose of

103 k course eradication therapy consisting of a proton pump inhibitor (PPI), amoxicillin, and clarithrom

104 When erlotinib is taken concurrently with a proton pump inhibitor (PPI), stomach pH increases, which

105 the value of skin tests in the diagnosis of proton pump inhibitor (PPI)-induced hypersensitivity rea

106 Between 1997 and 1999, 177 patients with proton pump inhibitor (PPI)-refractory GERD were randomi

107 tidyl peptidase IV inhibitor (DPP-4i), and a proton pump inhibitor (PPI).

108 de concomitant nonbismuth quadruple therapy (proton pump inhibitor [PPI] + amoxicillin + metronidazol

109 Histamine receptor-2 antagonist or proton pump inhibitor for 9 days of stress ulcer prophyl

110 in complex with a human drug substrate, the proton pump inhibitor omeprazole.

111 g methods, enhancing antibiotic and possibly proton pump inhibitor stewardship, and prescribing proph

112 agement considerations (potential indefinite proton pump inhibitor therapy and/or surveillance endosc

113 ce costs with survival benefit comparable to proton pump inhibitor therapy for stress ulcer prophylax

114 vironment created by surgical gastrectomy or proton pump inhibitor therapy in combination with a high

115 imal acid suppression (twice daily dosing of proton pump inhibitor therapy) in 8-12 weeks.

116 ase and this can be effectively treated with proton pump inhibitor therapy.

117 et agents, had a medical condition requiring proton pump inhibitor treatment, or had already received

118 additional recommendations by the panel were proton pump inhibitor use as a risk factor and the use o

119 Proton pump inhibitor use increases the risk of developi

120 Modification of proton pump inhibitor use may increase rates of SVR.

121 Manometric changes, pH testing, and proton pump inhibitor use were assessed preoperatively a

122 tinal bleeding and a possible association of proton pump inhibitor use with Clostridium difficile and

123 included Model for End-Stage Liver Disease, proton pump inhibitor use, and lower length of stay (c-s

124 g/dL), absence of cirrhosis, and absence of proton pump inhibitor use.

125 Omeprazole is a proton pump inhibitor used in the treatment of peptic ul

126 tamine receptor-2 antagonist and $7,802 with proton pump inhibitor, resulting in a cost saving of $1,

127 cy as the positive control of free drug plus proton pump inhibitor, the micromotors can function with

128 Patients (18-50 years) with proton pump inhibitor-resistant esophageal eosinophilia

129 role of gastroesophageal reflux disease and proton pump inhibitor-responsive esophageal eosinophilia

130 causes of esophageal eosinophilia, including proton pump inhibitor-responsive esophageal eosinophilia

131 cidifying the cytosol with bafilomycin A1, a proton pump inhibitor.

132 py and 8 weeks of maintenance therapy with a proton pump inhibitor; and 4) patients receiving follow-

133 omes in partial responders to high-dose (HD) proton-pump inhibitor (PPI) therapy and to evaluate dura

134 nic hepatitis C virus (HCV) are on prolonged proton-pump inhibitor (PPI) therapy and wish to remain o

135 d received either 10-day sequential therapy (Proton-Pump Inhibitor + Amoxicillin 1 g bid for 5 days a

136 hibitor + Amoxicillin 1 g bid for 5 days and Proton-Pump Inhibitor + Clarithromycin 500 mg + Metronid

137 Using full-dose proton-pump inhibitor and high-dose Metronidazole in gro

138 Using full-dose proton-pump inhibitor and higher doses of Metronidazole

139 dose Metronidazole in group A, and full-dose proton-pump inhibitor and prescription from a Gastroente

140 of the three trials, 124 (51%) were taking a proton-pump inhibitor or H2 blocker at enrolment.

141 use was defined as any pharmacy charge for a proton-pump inhibitor or histamine-2 receptor antagonist

142 that were either treated with omeprazole, a proton-pump inhibitor that suppresses acid secretion in

143 ephalosporin antibiotic) and lansoprazole (a proton-pump inhibitor) will prolong the QT interval.

144 Proton-pump inhibitor-responsive esophageal eosinophilia

145 re, with four (21%) of 19 patients needing a proton-pump inhibitor.

146 nce interval (CI): 2.1, 5.0), current use of proton pump-inhibitor antiheartburn medications (OR = 6.

147 BACKGROUND & AIMS: Proton pump inhibitors (PPI) are among the top 10 most p

148 BACKGROUND & AIMS: Proton pump inhibitors (PPI) have been associated with a

149 armacokinetic studies have demonstrated that proton pump inhibitors (PPI) reduce exposure of mycophen

150 The association between proton pump inhibitors (PPI) use and risk of acute inter

151 (NMA) was conducted to compare the different proton pump inhibitors (PPI) within triple therapy.

152 n open-label crossover trial to test whether proton pump inhibitors (PPIs) affect the gastrointestina

153 eported on the effects of concomitant use of proton pump inhibitors (PPIs) and dual antiplatelet ther

154 Proton pump inhibitors (PPIs) and histamine 2 receptor a

155 BACKGROUND & AIMS: Proton pump inhibitors (PPIs) and histamine-2 receptor a

156 Proton pump inhibitors (PPIs) and histamine-2 receptor a

157 The association between proton pump inhibitors (PPIs) and nontyphoid salmonellos

158 BACKGROUND & AIMS: Proton pump inhibitors (PPIs) are commonly used medicati

159 Proton pump inhibitors (PPIs) are popular drugs for gast

160 Proton pump inhibitors (PPIs) are widely used for the tr

161 Proton pump inhibitors (PPIs) are widely used to treat g

162 an FDA-approved drug database, we identified proton pump inhibitors (PPIs) as effective inhibitors of

163 reflux esophagitis successfully treated with proton pump inhibitors (PPIs) began 24-hour esophageal p

164 Proton pump inhibitors (PPIs) have been known to induce

165 Safety issues associated with proton pump inhibitors (PPIs) have recently attracted wi

166 Certain proton pump inhibitors (PPIs) interfere with clopidogrel

167 Proton pump inhibitors (PPIs) may be a risk factor for h

168 Recent studies suggest that proton pump inhibitors (PPIs) may increase the risk for

169 Proton pump inhibitors (PPIs) might reduce the risk of s

170 was use of acid suppression medication with proton pump inhibitors (PPIs) or histamine-2 receptor an

171 Proton pump inhibitors (PPIs) predispose to bacterial ov

172 ncreasing incidence of chronic liver disease.Proton pump inhibitors (PPIs) reduce gastric acid secret

173 Retrospective studies have suggested proton pump inhibitors (PPIs) reduce the need for phlebo

174 ross-sectional study, 8.5% of patients using proton pump inhibitors (PPIs) were rectal carriers of ex

175 monary disease (COPD), ulcer history, use of proton pump inhibitors (PPIs), aspirin, nonsteroidal ant

176 e the risks associated with long-term use of proton pump inhibitors (PPIs), focusing on long-term use

177 Proton pump inhibitors (PPIs), frequently prescribed to

178 cid-reducing agents, such as H2 blockers and proton pump inhibitors (PPIs), remains a controversial r

179 f this association is modulated by intake of proton pump inhibitors (PPIs).

180 s with IPF placed on antacid therapy such as proton pump inhibitors (PPIs).

181 nocarcinoma coincided with popularization of proton pump inhibitors and has focused attention on gast

182 phylaxis, review the comparative efficacy of proton pump inhibitors and histamine 2 receptor antagoni

183 MI patterns before and after treatment with proton pump inhibitors and to compare the performance of

184 r histamine 2 receptor antagonists; however, proton pump inhibitors appear to be the dominant drug cl

185 50% treatment-experienced, and 30% receiving proton pump inhibitors at start of treatment.

186 ibitor, the micromotors can function without proton pump inhibitors because of their built-in proton

187 The pharmacodynamic efficacy of proton pump inhibitors has not been specifically evaluat

188 While proton pump inhibitors have been widely used for blockin

189 e macular degeneration patients treated with proton pump inhibitors having the core structure, 2-pyri

190 ating the efficacy and safety of withholding proton pump inhibitors in critically ill patients.

191 per gastrointestinal bleeding; the effect of proton pump inhibitors on ventilator-associated pneumoni

192 ally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonis

193 ux, defined as use of antireflux medication (proton pump inhibitors or histamine2 receptor antagonist

194 ot clearly support lower bleeding rates with proton pump inhibitors over histamine 2 receptor antagon

195 Here, we show that proton pump inhibitors promote progression of alcoholic

196 In critically ill patients, proton pump inhibitors seem to be more effective than hi

197 d controlled parallel group trials comparing proton pump inhibitors to histamine 2 receptor antagonis

198 meta-analyzed five trials (604 patients) of proton pump inhibitors versus placebo; there was no stat

199 H2RAs compared with proton pump inhibitors were not significantly different

200 Proton pump inhibitors were stopped at least 7 days befo

201 , change in body mass index, smoking, use of proton pump inhibitors, and anti-diabetic medications, a

202 Lifestyle modifications, proton pump inhibitors, and laparoscopic fundoplication

203 , GORD, endoscopy, manometry, pH monitoring, proton pump inhibitors, and Nissen fundoplication.

204 interactions with H2-receptor antagonists or proton pump inhibitors, does not cause central nervous s

205 , GORD, endoscopy, manometry, pH monitoring, proton pump inhibitors, open fundoplication, and laparos

206 Proton pump inhibitors, thyroid hormones, and dihydropyr

207 that esophageal eosinophilia can respond to proton pump inhibitors.

208 asibility before and after administration of proton pump inhibitors.

209 long-term history of diarrhea, responsive to proton pump inhibitors.

210 tions were similar when we excluded users of proton pump inhibitors.

211 but the survival benefit of 0.0167% favored proton pump inhibitors.

212 onomic problem, due to the widespread use of proton pump inhibitors.

213 Results for proton-pump inhibitors (2.1 percentage points [CI, -3.7

214 The association was significant for proton-pump inhibitors (OR = 2.7, 95% CI = 1.4-5.4), but

215 Consequently, although co-prescription of proton-pump inhibitors (PPIs) reduces upper gastrointest

216 f Gastrointestinal Events Trial) showed that proton-pump inhibitors (PPIs) safely reduced rates of ga

217 reased, reflux symptoms improved, and use of proton-pump inhibitors decreased.

218 eatment using tetracycline, furazolidone and proton-pump inhibitors has been effective and low cost i

219 t that dipeptidyl peptidase-4 inhibitors and proton-pump inhibitors might enhance beta-cell survival

220 es, a reduction of 50% or more in the use of proton-pump inhibitors occurred in 93% of patients, and

221 No proton-pump inhibitors were administered during follow-u

222 idemic agents, antidepressants, prescription proton-pump inhibitors, and muscle relaxants.

223 hese patients were successfully treated with proton-pump inhibitors.

224 neric-equivalent beta-blockers, statins, and proton-pump inhibitors.

225 essed at baseline while they were not taking proton-pump inhibitors.

226 and reminders to reduce inappropriate use of proton-pump inhibitors.

227 lar-type ATPases (V-ATPases) are ATP-powered proton pumps involved in processes such as endocytosis,

228 Proton pumping is achieved by means of rotary motors, na

229 ur results elucidate the mechanisms by which proton pumping is impaired, thus revealing key kinetic g

230 Proton pumping is paramount to keep normal cells alive,

231 onstrate that a mutant lacking both of these proton pumps is conditionally viable and retains signifi

232 se) of Toxoplasma gondii (TgVP1), a membrane proton pump, localizes to acidocalcisomes and a novel ly

233 The minimal proton pumping machinery of the Arabidopsis thaliana P-t

234 step plays a central role in activating the proton pumping machinery.

235 In particular, the proton-pumping machinery of these Coxs has not yet been

236 re subunit may be combined with quantitative proton-pumping measurements for mechanistic studies.

237 -copper center of O2 reduction initiates the proton pump mechanism.

238 Thus, the same proton pumping mechanism can be used each time CcO is re

239 To better understand the proton-pumping mechanism of the wild-type (WT) CcO, much

240 Mitochondrial proton-pumping NADH:ubiquinone oxidoreductase (respirato

241 Mitochondrial complex I (proton-pumping NADH:ubiquinone oxidoreductase) is an ess

242 the retinal Schiff base in the light-driven proton pump of Exiguobacterium sibiricum (ESR).

243 Bafilomycin, an inhibitor of the vacuolar proton pump of lysosomes and endosomes that causes lysos

244 Contrary to the proton pumps of known structure, ESR possesses three uni

245 roton gradient, ultimately maintained by the proton pumps of the respiratory chain, and Ca(2+) bindin

246 iposomes containing a bacteriorhodopsin (bR) proton pump onto the nanowire surface.

247 Cytochrome bo3 is a respiratory proton-pumping oxygen reductase that is a member of the

248 olecule level the activity of the prototypic proton-pumping P-type ATPase Arabidopsis thaliana isofor

249 old compared with CEF pathways involving non-proton-pumping plastoquinone reductases.

250 glucose is limiting, however, an ATP-driven proton pump (Pma1) is inactivated, leading to a marked d

251 ing susceptibility to edelfosine with the PM proton pump Pma1p playing a main role.

252 ptosomal mitochondria and synaptic vesicular proton pump protein (V-ATPase H) levels.

253 to orient the insertion of the light-driven proton pump proteorhodopsin (PR) into liposomes.

254 ein to function as both a redox enzyme and a proton pump, proton transfer into the protein toward the

255 protein to function as both redox enzyme and proton pump, proton transfer out of either of the channe

256 ean bacterioplankton, where its light-driven proton pumping provides energy to cells.

257 of Arabidopsis (Arabidopsis thaliana) type I proton-pumping pyrophosphatase (AVP1) in phloem loading

258 We conclude that the Proton-Pumping Pyrophosphatase AVP1 localized at the pla

259 Proton-pumping pyrophosphatases (H(+)-PPases) are shown

260 equence homology with haloarchaeal rhodopsin proton pumps rather than with previously known channelrh

261 as acidification was prevented by blocking a proton pump, re-alkalinization was prevented by blocking

262 llular membrane surface by a light-activated proton pump recruited a slow inward ASIC current, which

263 (V-ATPases) are highly conserved, ATP-driven proton pumps regulated by reversible dissociation of its

264 Proton pumping requires that residues on a pathway chang

265 he ATP4A gene (c.2107C>T), which encodes the proton pump responsible for acid secretion by gastric pa

266 Finally, a new clade of likely proton-pumping rhodopsin with non-canonical amino acids

267 Proton-pumping rhodopsins (PPRs) are photoactive retinal

268 Some function as outward proton pumps, some as inward chloride pumps, whereas oth

269 Measurement of proton pumping stoichiometry is challenging because, eve

270 The proton-pumping stoichiometry of complex I (i.e. the numb

271 describe a simple method for determining the proton-pumping stoichiometry of complex I in inverted me

272 By virtue of this proton-pumping stoichiometry, we hypothesize that NADPH

273 onsible for the delivery of electrons to the proton pumping subunit.

274 on of the vacuolar H(+)-ATPase (V-ATPase), a proton pump that acidifies lysosomes.

275 ar ATPase (V-ATPase) is a 1MDa transmembrane proton pump that operates via a rotary mechanism fuelled

276 hodopsin (GR) are retinal-based light-driven proton pumps that absorb visible light (maxima at 520-54

277 V-ATPases are conserved ATP-driven proton pumps that acidify organelles.

278 Vacuolar ATPases (V-ATPases) are essential proton pumps that acidify the lumen of subcellular organ

279 Pases (V-ATPases) are a family of ATP-driven proton pumps that couple ATP hydrolysis with translocati

280 (+) ATPases) are multisubunit, ATP-dependent proton pumps that regulate pH homeostasis in virtually a

281 lar pH is primarily driven by the V-ATPases, proton pumps that use cytoplasmic ATP to load H(+) into

282 established by the combined activity of two proton pumps, the vacuolar H(+)-pyrophosphatase (V-PPase

283 ype ATPase and compromised targeting of this proton pump to the plasma membrane upon acid challenge.

284 where it is functionally coupled with apical proton pumps to maintain normal acid-base homeostasis.

285 sensitive alternative oxidase (AOX) is a non-proton-pumping ubiquinol oxidase that catalyzes the redu

286 site in the hydrophilic arm to four putative proton-pumping units.

287 ple allow proton transfer to the BNC, but no proton pumping until a proton has reached E286.

288 The ATP-dependent proton pump V-ATPase ensures low intralysosomal pH, whic

289 The membrane sector (Vo) of the proton pumping vacuolar ATPase (V-ATPase, V1Vo-ATPase) f

290 Renal intercalated cells (ICs) express the proton pumping vacuolar H(+)-ATPase (V-ATPase) and are e

291 t mutants lacking the intracellular V-ATPase proton pump (vma mutants) have reduced levels of the Pma

292 n ATPase, normally coupled to membrane-bound proton pump Vo via a rotary mechanism.

293 Thr/Asp-132-Asn mutant cytochrome c oxidase, proton pumping was impaired, which indicates that the se

294 In this structural variant, proton pumping was uncoupled from internal electron tran

295 l seven-transmembrane light-driven bacterial proton pump, we find evidence that the inter-protein int

296 elucidate the mechanism of the redox-driven proton pumping, we investigated the kinetics of electron

297 ining bacteriorhodopsin (bR), a light-driven proton pump, were arranged on a common hydrogel surface

298 Vps34 lipid kinase complex and the v-ATPase proton pump, whereas Atg genes involved in macroautophag

299 The V-ATPase is a multisubunit, rotary proton pump whose precise role in homotypic fusion is co

300 -2 (KR2), a microbial light-driven sodium or proton pump, with noncovalent mass-spectrometric, electr